• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Disease Prevention and Control, San Francisco Department of Public HealthPopulation Health Division SF Department of Public HealthPopulation Health Division SF Department of Public Health

  • Infectious Diseases A to Z
  • About
  • Contact
  • Home
  • Communicable Disease
    • 24/7 Disease Reporting
      • Disease Reporting: Additional Information for Medical Providers
      • Influenza Reporting
      • Frequently Requested Phone Numbers 
    • Healthy Habits
      • How to Put on and Remove a Face Mask 
    • Publications, Data, and Reports
    • Infection Control
      • Infection Prevention and Control for Health Care Settings
      • Infection Prevention and Control for Long-Term Care Facilities
    • Infectious Diseases A to Z
  • Immunizations
    • Vaccines You Need
      • Adults
      • Children & Adolescents
      • Vaccines for Gay and Bisexual Men
    • Where to Get Immunized
    • Influenza (Flu)
    • Vaccine Safety
    • Immunization Programs
      • Flu Vaccine Programs: Ordering Information for Health Care Providers
      • Hepatitis Programs
        • Hepatitis Education
        • Hepatitis Vaccine Distribution Program
        • Perinatal Hep B Program
        • Programs for Asian and Pacific Islanders
      • California Immunization Registry (CAIR)
      • Vaccines for Children
      • San Francisco Immunization Coalition
      • Emergency Mass Prophylaxis Clinic Planning
    • Schools and Child Care
    • Resources & Materials
      • Vax Facts: Vaccine Updates
      • Immunization Links
      • Request Materials
      • Vaccine Management Plan
    • Information for Medical Providers
    • Provider Spotlight
  • AITC Immunization & Travel Clinic
    • International Travelers
      • Promoting Travelers’ Health
      • Yellow Fever Vaccine FAQ (Frequently Asked Questions)
    • Immunization & Testing
    • Services for Businesses
    • Contact, Location, Hours, and Payments
    • Plan Your Visit
    • Prices
      • Low-Cost or Free Vaccines at AITC
    • Forms
    • Links
    • About AITC
  • Health Alerts & Emergencies
    • Prepare
    • Health Alerts
      • Sign Up For Health Alerts
    • Infectious Disease Plan
      • Emergency Exercises
    • Clinician Emergency Guide
    • Recognizing Bioterrorism
    • Programs and Activities
  • Tuberculosis Control
    • Tuberculosis Services
    • Tuberculosis Information For Medical Providers
      • LTBI Referral (Specific to Civil Surgeons)
      • Tuberculosis Screening Guidelines
        • Tuberculosis Testing
      • Tuberculosis Clinic Referrals Criteria
      • Managing Positive Reactions
      • Suspected/Confirmed Active TB Reporting
      • LTBI Risk Assessment Tools and Treatment Guidelines
      • Hospital Discharge
      • QuantiFERON Information
      • Infection Control Guidelines
      • Shelter Client Screening Guidelines
      • TB Resources for the Public
    • Publications
    • Reports
    • Links
    • San Francisco Tuberculosis Prevention and Control Program (SFTBPCP) Supplemental Information
  • Public Health Laboratory
    • Laboratory Contact Information
    • Check COVID-19 and Influenza Test Results Online
    • Non-Diagnostic General Health Assessments (NGHA)
    • General Specimen Submission Guidelines
    • Forms for Specimen and Culture Submission
    • Laboratory Test Menu
  • STD Services
  • Infectious Diseases A to Z
  • About

Recommendations for Latent TB Infection Screening and Treatment during Pregnancy

The Centers for Disease Control and Prevention (CDC) and the National TB Controllers Association (NTCA) recommend that all pregnant persons with risk factors for active TB should undergo screening for TB infection1. Babies born to persons with active TB may have lower birth weight and are at potential risk for congenital TB with associated high mortality. Additionally,   infectiousness at delivery could expose both health care providers and the newborn.

TB testing with a tuberculin skin test (TST) in US-born or interferon-gamma release assay (IGRA) in non-US born is indicated in pregnant persons with the following risk factors:

  • Non-US-born from a country with high TB endemicity
  • HIV or immunocompromised status
  • History of contact with a person with infectious TB disease during lifetime

See the California Department of Public Health TB Risk Assessment for details.

Positive TST or IGRA

Pregnant person with a positive TB test result should receive a medical evaluation, including a chest radiograph (CXR) with a lead shield. The CXR may be deferred until after the first trimester. The CXR should be done as soon as possible if the following are present:

  • HIV or other immunosuppression
  • History of recent contact with a person with infectious TB disease
  • Documented TB infection test conversion in the past 2 years

For all others, the CXR may be deferred to the second trimester. In general, if person has had a normal CXR in the 3 months prior to medical evaluation and is asymptomatic, a repeat CXR is not necessary.

If the CXR has abnormalities suggestive of active TB disease per radiology report, refer to SFDPH TB Clinic as soon as possible. Contact us at 628 206-8524.

Treatment

If the CXR is normal, the decision of whether to treat latent TB infection (LTBI) during pregnancy should be made on a case-by-case basis. Prenatal visits represent a unique opportunity for treatment of latent TB, as maternal health care benefits may be lost within a few weeks/months after delivery and many persons may only access medical care when pregnant. If treatment is deferred, a referral should be made to the primary care provider to treat the LTBI.

Recommendations to delay LTBI treatment during pregnancy have largely been based on increased risk of hepatotoxicity with isoniazid. 3HP has not been studied and should not be offered. Increase in risk has not been documented with rifampin-only based regimens.

Per NTCA guidance, SFDPH recommends persons with uncomplicated pregnancy can be treated for LTBI with rifampin 600 mg po daily x 4 months1.

  • If the person has risk factors (e.g., HIV or other immunosuppression, history of recent contact with a person with infectious TB diseases or is a documented convertor in the past 2 years), strongly encourage LTBI treatment as soon as possible.
  • Educate on monitoring for liver toxicity (anorexia, new nausea, vomiting, abdominal pain, jaundice etc).
  • Counsel on the presence of nitrosamines in rifampin. In general, per the FDA, nitrosamine impurities have been shown to be potential carcinogens in animal studies with high nitrosamine exposure over prolonged periods of time (e.g., the equivalent of years-decades).  The benefits of treatment with short-course rifampin for latent TB far outweigh any potential risk from nitrosamine exposure5.
  • Once rifampin is started, obtain baseline and monthly liver function tests.
  • If rifampin is contraindicated, considering deferring treatment until 3-6 months post-partum given risk for transaminitis with isoniazid and because there is little safety data on rifabutin.
  • If LTBI treatment extends into the post-partum period, remind patient that rifampin is safe to take while breast-feeding for both infant and mother.

References 

  1. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2022. Available at URL: https://www.tbcontrollers.org/resources/tb-infection/clinical-recommendations/
  2. FDA Updates and Press Announcements on Nitrosamines in Rifampin and Rifapentine.  Available at URL:

https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-nitrosamines-rifampin-and-rifapentine. Updated Jan 28, 2021.

Print PDF Version: https://www.sfcdcp.org/wp-content/uploads/2022/12/SFDPH-TB-Clinic-Recommendations-pregnant-1.pdf

Primary Sidebar

Tuberculosis Control

  • Tuberculosis Services
    • Tuberculosis Testing Sites
  • Tuberculosis Information For Medical Providers
    • LTBI Referral (Specific to Civil Surgeons)
    • Tuberculosis Screening Guidelines
      • Tuberculosis Testing
    • Tuberculosis Clinic Referrals Criteria
    • Managing Positive Reactions
    • Suspected/Confirmed Active TB Reporting
    • LTBI Risk Assessment Tools and Treatment Guidelines
    • Hospital Discharge
    • QuantiFERON Information
    • Infection Control Guidelines
    • Shelter Client Screening Guidelines
    • TB Resources for Trainees
    • Sputum Collection for Primary Care Providers
    • Recommendations for Latent TB Infection Screening and Treatment during Pregnancy
    • TB Risk and Targeted Immunotherapy/Biologics Recommendations
  • TB Resources for the Public
  • Publications
  • Reports
  • Links
  • San Francisco Tuberculosis Prevention and Control Program (SFTBPCP) Supplemental Information

CMR Forms

Medical providers: download the Confidential Morbidity Report (CMR) form to report a communicable disease

CMR Form

or download the COVID-19 CMR form to report COVID-19 hospitalizations, deaths and POC testing by HCPs

COVID-19 CMR Form

Footer

Contact

SF Dept of Public Health
101 Grove Street
San Francisco, CA 94102
(415) 554-2500

Web Links

  • SF Dept. of Public Health
  • City and County of San Francisco

Privacy Policy | Sitemap | Contact Us
Website by MIGHTYminnow

© Copyright 1998 - 2023, Department of Public Health, City and County of San Francisco